Skip to main content
SpringerLink
Log in

Antidepressant-induced hyperprolactinaemia

incidence, mechanisms and management

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Prolactin, a polypeptide hormone, is responsible, amongst other things, for milk production during lactation and breast enlargement during pregnancy. Numerous drugs can affect prolactin levels. Most commonly, conventional antipsychotics are associated with hyperprolactinaemia but there have also been reports of antidepressants causing hyperprolactinaemia. This review sets out to establish the incidence of antidepressant-induced hyperprolactinaemia, its possible mechanism and to determine appropriate remedial actions. Nearly all antidepressants are reported to be associated with hyperprolactinaemia. Incidence rates were not clearly established and symptoms were very rare. The mechanism by which antidepressants may cause hyperprolactinaemia is not fully understood, though several theories have been postulated, such as serotonin stimulation of GABAergic neurons and indirect modulation of prolactin release by serotonin. Patients taking antidepressants presenting to their clinician with symptoms potentially related to hyperprolactinaemia, such as galactorrhoea, should have their plasma prolactin level measured and their antidepressant changed if an increased prolactin level is confirmed. Routine monitoring of prolactin levels is otherwise not appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80(4): 1523–631

    PubMed  CAS  Google Scholar 

  2. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19(3): 225–68

    Article  PubMed  CAS  Google Scholar 

  3. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724–63

    Article  PubMed  CAS  Google Scholar 

  4. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3(5): 929–51

    PubMed  Google Scholar 

  5. Leung A, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician 2004; 70(3): 543–50

    PubMed  Google Scholar 

  6. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314

    Article  PubMed  CAS  Google Scholar 

  7. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349(21): 2035–41

    Article  CAS  Google Scholar 

  8. Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008; 11(2): 141–6

    Article  PubMed  CAS  Google Scholar 

  9. Holt RI. Medical causes and consequences of hyperprolactinaemia: a context for psychiatrists. J Psychopharmacol 2008; 22(2 Suppl. ): 28–37

    Article  PubMed  Google Scholar 

  10. Todd J. Prolactin disorders. Medicine 2005; 33(11): 16–7

    Article  Google Scholar 

  11. Meltzer HY, Piyakalmala S, Schyve P, et al. Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology (Berl) 1977; 51(2): 185–7

    Article  CAS  Google Scholar 

  12. Meltzer HY, Fang VS, Tricou BJ, et al. Effect of antidepressants on neuroendocrine axis in humans. Adv Biochem Psychopharmacol 1982; 32: 303–16

    PubMed  CAS  Google Scholar 

  13. Fava GA, Lisansky J, Buckman MT, et al. Prolactin, cortisol, and antidepressant treatment. Am J Psychiatry 1988; 145(3): 358–60

    PubMed  CAS  Google Scholar 

  14. Charney DS, Heninger GR, Sternberg DE. Serotonin function and mechanism of action of antidepressant treatment: effects of amitriptyline and desipramine. Arch Gen Psychiatry 1984; 41(4): 359–65

    Article  PubMed  CAS  Google Scholar 

  15. Price LH, Charney DS, Delgado PL, et al. Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan: serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 1989; 46(7): 625–31

    Article  PubMed  CAS  Google Scholar 

  16. Shapira B, Reiss A, Kaiser N, et al. Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affect Disord 1989; 16(1): 1–4

    Article  PubMed  CAS  Google Scholar 

  17. Anderson IM, Cowen PJ. Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Psychopharmacology (Berl) 1986; 89(1): 131–3

    Article  CAS  Google Scholar 

  18. Gadd EM, Norris CM, Beeley L. Antidepressants and galactorrhoea. Int Clin Psychopharmacol 1987; 2(4): 361–3

    Article  PubMed  CAS  Google Scholar 

  19. Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br J Psychiatry 1985; 147: 87–8

    Article  PubMed  CAS  Google Scholar 

  20. Fowlie S, Burton J. Hyperprolactinaemia and nonpuerperal lactation associated with clomipramine [letter]. Scott Med J 1987; 32(2): 52

    PubMed  CAS  Google Scholar 

  21. Slater SL, Lipper S, Shiling DJ, et al. Elevation of plasmaprolactin by monoamine-oxidase inhibitors. Lancet 1977; 2(8032): 275–6

    Article  PubMed  CAS  Google Scholar 

  22. Price LH, Charney DS, Heninger GR. Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 1985; 37(9): 809–18

    Article  PubMed  CAS  Google Scholar 

  23. Egberts AC, Meyboom RH, De Koning FH, et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 1997; 44(3): 277–81

    Article  PubMed  CAS  Google Scholar 

  24. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152(1): 122–5

    PubMed  CAS  Google Scholar 

  25. Sagud M, Pivac N, Muck-Seler D, et al. Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 2002; 45(3): 139–43

    Article  PubMed  CAS  Google Scholar 

  26. Gordon C, Whale R, Cowen PJ. Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology 1998; 137(2): 201–2

    Article  PubMed  CAS  Google Scholar 

  27. Schlösser R, Wetzel H, Dorr H, et al. Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology 2000; 25(4): 377–88

    Article  PubMed  Google Scholar 

  28. Seifritz E, Baumann P, Muller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males: a placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996; 14(4): 253–63

    Article  PubMed  CAS  Google Scholar 

  29. Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 1999; 88(2): 75–88

    Article  PubMed  CAS  Google Scholar 

  30. Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa. Psychoneuroendocrinology 2006; 31(10): 1139–48

    Article  PubMed  CAS  Google Scholar 

  31. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004; 29(9): 1699–703

    Article  PubMed  CAS  Google Scholar 

  32. Henning J, Netter P. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Int J Neuropsychopharmacol 2002; 5(1): 67–71

    PubMed  CAS  Google Scholar 

  33. Hawken ER, Owen JA, Van VD, et al. Effects of oral racemic citalopram on neuroendocrine responses. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(4): 694–700

    Article  PubMed  CAS  Google Scholar 

  34. Moeller O, Hetzel G, Rothermundt M, et al. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 2003; 37(3): 261–2

    Article  PubMed  Google Scholar 

  35. Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001; 76(2): 215–6

    PubMed  CAS  Google Scholar 

  36. Morrison J, Remick RA, Leung M, et al. Galactorrhea induced by paroxetine. Can J Psychiatry 2001; 46(1): 88–9

    PubMed  CAS  Google Scholar 

  37. Shim SH, Lee YJ, Lee EC. A case of galactorrhea associated with escitalopram. Psychiatry Investig 2009; 6: 230–2

    Article  PubMed  CAS  Google Scholar 

  38. Aggarwal A, Kumar R, Sharma RC, et al. Escitalopram induced galactorrhoea: a case report. Prog Neuropscyhopharmacol Biol Psychiatry 2010; 34: 557–8

    Article  Google Scholar 

  39. Daffner-Bugia C, Laakmann G, Voderholzer U, et al. The neuroendocrine effects of venlafaxine in healthy subjects. Hum Psychopharmacol 1996; 11: 1–9

    Article  CAS  Google Scholar 

  40. Bhatia SC, Bhatia SK, Bencomo L. Effective treatment of venlafaxine-induced noncyclical mastalgia with bromocriptine. J Clin Psychopharmacol 2000; 20(5): 590–1

    Article  PubMed  CAS  Google Scholar 

  41. Sternbach H. Venlafaxine-induced galactorrhea. J Clin Psychopharmacol 2003; 23(1): 109–10

    Article  PubMed  Google Scholar 

  42. Ashton AK, Longdon MC. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry 2007; 164(7): 1121–2

    Article  PubMed  Google Scholar 

  43. Schule C, Baghai T, Schmidbauer S, et al. Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 2004; 29(2): 185–200

    Article  PubMed  CAS  Google Scholar 

  44. Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24: 769–84

    Article  PubMed  CAS  Google Scholar 

  45. Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163: 95–101

    Article  CAS  Google Scholar 

  46. Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20: 101–3

    Article  PubMed  CAS  Google Scholar 

  47. Schüle, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79: 54–62

    Article  PubMed  Google Scholar 

  48. Laakmann G, Schule C, Baghai T, et al. Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 1999; 24(7): 769–84

    Article  PubMed  CAS  Google Scholar 

  49. Schule C, Baghai T, Goy J, et al. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berl) 2002; 163(1): 95–101

    Article  CAS  Google Scholar 

  50. Laakmann G, Schule C, Baghai T, et al. Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol 2000; 20(1): 101–3

    Article  PubMed  CAS  Google Scholar 

  51. Schule C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004; 79(1): 54–62

    Article  PubMed  Google Scholar 

  52. Whiteman PD, Peck AW, Fowle ASE, et al. Bupropion fails to affect plasma prolactin and growth hormone in normal subjects [letter]. Br J Clin Pharmacol 1982; 13(743): 745

    Google Scholar 

  53. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry 1993; 150(8): 1269–70

    PubMed  CAS  Google Scholar 

  54. Electronic Medicines Compendium. Seroxat 10 mg, 20 mg, 30mg tablets, 20mg/10mL oral suspension: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc [Accessed 2010 May 6]

  55. Electronic Medicines Compendium. Anafranil capsules: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc [Accessed 2010 May 6]

  56. Electronic Medicines Compendium. Cipramil tablets: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc [Accessed 2010 May 6]

  57. Electronic Medicines Compendium. Lustral: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc [Accessed 2010 May 6]

  58. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004; 29(5): 833–46

    Article  PubMed  CAS  Google Scholar 

  59. Rittenhouse PA, Levy AD, Li Q, et al. Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1C/2 receptors. Endocrinology 1993; 133(2): 661–7

    Article  PubMed  CAS  Google Scholar 

  60. Jorgensen H, Knigge U, Warberg J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology 1992; 55(3): 336–43

    Article  PubMed  CAS  Google Scholar 

  61. Sonino N, Tomba E, Fava GA. Psychosocial approach to endocrine disease. Adv Pharmacother 2007; 28: 21–33

    Google Scholar 

  62. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5): 485–91

    PubMed  CAS  Google Scholar 

  63. Klein JJ, Segal RL, Warner RR. Galactorrhea due to imipramine: report of a case. N Engl J Med 1964; 271: 510–2

    Article  PubMed  CAS  Google Scholar 

  64. Wolfsperger M, Greil W. Galactorrhea during treatment with trimipramine: a case report. Pharmacopsychiatry 2005; 38(6): 326–7

    Article  PubMed  CAS  Google Scholar 

  65. Bonin B, Vandel P, Sechter D, et al. Paroxetine and galactorrhea. Pharmacopsychiatry 1997; 30(4): 133–4

    Article  PubMed  CAS  Google Scholar 

  66. Ghosal M, Mukhopadhyay S, Sanyal D. A case of paroxetine-inducted galactorrhoea. German J Psychiatry 2005; 8: 23–4

    Google Scholar 

  67. Davenport E, Velamoor R. A case of paroxetine-induced galactorrhea. Can J Psychiatry 2002; 47(9): 890–1

    PubMed  Google Scholar 

  68. Gonzalez E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment [letter]. Pharmacopsychiatry 2000; 33(3): 118

    Article  PubMed  CAS  Google Scholar 

  69. Yalug I, Tural U, Unsalan N, et al. Reboxetine may cause amenorrhea in female patients. Int J Psychiatry Clin Pract 2006; 10(3): 223–5

    Article  Google Scholar 

  70. Gulsun M, Algul A, Semiz UB, et al. A case with euprolactinemic galactorrhea induced by escitalopram. Int J Psychiatry Med 2007; 37: 275–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Prof. Taylor has received consultancy fees, research funding and honoraria from Servier, Lundbeck, Eli Lilly and Wyeth. Miss Coker has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Pharmacy Department, Maudsley Hospital, Denmark Hill, London, SE5 8AZ, UK

    Flora Coker &  David Taylor

  2. Divison of Pharmaceutical Sciences, King’s College, London, UK

    David Taylor

Authors
  1. Flora Coker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Taylor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coker, F., Taylor, D. Antidepressant-induced hyperprolactinaemia. CNS Drugs 24, 563–574 (2010). https://doi.org/10.2165/11533140-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533140-000000000-00000

Keywords

Search

Navigation